Hundreds of lawsuits have been filed against the makers of widely used weight-loss and diabetes drugs, alleging the medicines caused a rare eye condition that can lead to sudden and potentially permanent vision loss.
The cases target Novo Nordisk and Eli Lilly over several GLP-1 drugs, including Ozempic, Wegovy, Mounjaro and Zepbound, and centre on non-arteritic anterior ischaemic optic neuropathy, known as NAION.